News
Update – Workpackage 4
02/02/24

We have been able to set up an innovative analysis pipeline to overcome the limitations of conventional approaches, and thus achieve our objective of defining a clinico-biological score for HAP classifying individual risk of and predicting response to immunotherapy. Our clinico-biological score comprises 4 metabolites that can be used to classify patients into three levels of risk of HAP. This score is associated with response to interferon gamma 1b treatment. Our results will be published shortly.
We thank the Pays de la Loire Region for making it possible to recruit a post-doctoral fellow, and for contributing to the development of predictive scores for hospital-acquired pneumonia and response to treatments.